Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

Lower prescription drug costs via Medicare for All unlikely – and prescription drugs only account for 10 percent of national health expenses.

Charles Blahous J. Fish and Lillian F. Smith 2018 The Costs of a National Single-Payer Healthcare System MERCATUS WORKING PAPER George Mason University. https://www.mercatus.org/research/working-papers/costs-national-single-payer-healthcare-system

This analysis credits the M4A proposal with approximately $846 billion in additional savings over the 2022–2031 period from negotiating lower prices for prescription drugs. This is an aggressive assumption reflecting the intent of the bill to empower the secretary of Health and Human Services (HHS) to negotiate lower drug prices on behalf of beneficiaries and specifically to “promote the use of generic medications to the greatest extent possible.”31 There are limits to the potential effectiveness of this approach to lowering healthcare costs. Generics have prices 75 to 90 percent lower than those of brand-name drugs, but they already make up roughly 85 percent of all prescription drugs sold.3 Additionally, prescription drugs account for only 10 percent of total national health expenditures.33 This analysis assumes virtually perfect success for M4A in replacing brand-name drugs with generics, both for those now on Medicare as well as for the population as a whole; therefore, actual savings are likely to be less than assumed under these projections.34 It is a matter of wide speculation whether granting negotiating power to the HHS secretary could produce savings beyond these aggressive assumptions with respect to generic drug penetration.35 Even if such a grant of power achieved greater savings, however, such additional savings are likely to be offset by imperfect success in eliminating brand-name drug purchases in favor of generics.36 These cost estimates do not reflect other potential effects of the proposed policy, such as lessened pharmaceutical innovation.

Sign in to recut, update, or save this card.